top of page

APLEX Bio recognized as impact company by EQT Foundation


11 dec. 2022

What EQT Foundation loves about APLEX Bio

APLEX Bio’s multiplex solution radically disrupts current molecular detecting models, identifying such a vast number of different pathogens in just one test. EQT Foundation finds the technology most interesting as this enables access to reliable diagnostic testing in a cost-effective way, giving doctors the possibility to achieve highly parallelized detection of biomarkers in a new, easy way. In for example low-resource settings, where individual testing is not possible, there is great potential to serve underserved groups globally, using for example wastewater-based epidemiology to monitor public health in an efficient and cost-effective way.

Read more:

bottom of page